NCT07053384 - A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

February 24, 2027

Study Completion Date

March 24, 2028

Conditions

HIV Infections

Interventions

BIOLOGICAL

VH3810109

VH3810109 will be administered.

DRUG

Fostemsavir (FTR)

Fostemsavir will be administered.

DRUG

SOC INSTI-based ART

A SOC INSTI-based ART regimen will be administered.

Trial Locations (9)

32803

RECRUITING

GSK Investigational Site, Orlando

34982

RECRUITING

GSK Investigational Site, Ft. Pierce

45267

RECRUITING

GSK Investigational Site, Cincinnati

63110

RECRUITING

GSK Investigational Site, St Louis

64111

RECRUITING

GSK Investigational Site, Kansas City

75208

RECRUITING

GSK Investigational Site, Dallas

75246

RECRUITING

GSK Investigational Site, Dallas

92103

RECRUITING

GSK Investigational Site, San Diego

93301

RECRUITING

GSK Investigational Site, Bakersfield